Breaking News, Collaborations & Alliances

Nascent Biotech & HypoSpray Pharma Collaborate on Proprietary Transdermal Delivery System

Aim to eliminate bi-weekly weekly infusions, allowing patients to administer Pritumumab and avoid multi hour cancer center treatment visits.

Author Image

By: Charlie Sternberg

Associate Editor

Nascent Biotech Inc., a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma, a clinical and commercial stage drug delivery technology company, have joined forces to develop an alternative delivery mechanism for patients who can benefit from Pritumumab (PTB), Nascent’s lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer.   Once successfully comme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters